Fluorescent In Situ Hybridization Probe Market To Reach $1.49 Billion By 2030

Fluorescent In Situ Hybridization Probe Market Growth & Trends

The global fluorescent in situ hybridization probe market size is expected to reach USD 1.49 billion by 2030, registering a CAGR of 7.6% over the forecast period. The increasing global population being prone to target diseases, such as cancer, leads to the rising demand for accurate and effective diagnostics. This is expected to boost the market growth. For instance, according to the American Cancer Society Cancer Statistics 2023, it was estimated that approximately 1.9 million new cancer cases will be diagnosed in the U.S. in 2023. The Australian Institute of Health and Welfare (AIHW) 2021 report indicates that there were an estimated 150,782 new cancer cases in Australia in 2021.

Furthermore, the ICMR 2021 Report suggests that the number of cancer patients in India is projected to increase from 26.7 million in 2021 to 29.8 million in 2025. The fluorescent in situ hybridization (FISH) technique serves various purposes, including the precise localization of specific DNA sequences, genetic disease diagnosis, gene mapping, and identification of new oncogenes associated with different types of cancers. The growing investment in cancer genomics is expected to drive the adoption and significance of FISH. In addition, supportive government initiatives, rising healthcare expenditure levels, and increasing awareness pertaining to the benefits associated with this technique are expected to fuel industry growth during the forecast period.

Furthermore, technological advancement in chromogenic in situ hybridization (CISH), such as higher storage time of analyzed samples for long-duration studies, is expected to fuel the demand for navigation systems in the coming years. FISH is most commonly used in the detection of genetic diseases, such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down’s syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia (ALL), and cri-du-chat. According to a publication from the CDC in 2022, Down’s syndrome is the most common genetic disorder, with almost one in every 700 newborns affected by the disorder.

The rising prevalence of the condition drives the need to provide efficient diagnostics for detecting these genetic diseases, which, in turn, drives the overall market growth. Furthermore, key participants are engaged in various strategies, such as product launches, partnerships & collaborations, and M&As, to expand their global footprint and maintain competitive position in the market. For instance, in March 2023, OGT (Sysmex Group) received IVDR certification for CytoCell FISH probes. The company is the first manufacturer of FISH probes to receive IVDR certification, showcasing its unwavering commitment to meeting the significantly more rigorous regulatory standards. This certification validates their products' enduring safety, dependability, and efficacy.

 Request a free sample copy or view report summary: Fluorescent In Situ Hybridization Probe Market Report

Fluorescent in Situ Hybridization Probe Market Report Highlights

• On the basis of technology, the flow FISH segment dominated the market in 2022 owing to the high demand for diagnosis of bacterial, viral, and fungal diseases

• On the basis of type, miRNA is anticipated to grow at a significant CAGR over the forecast period driven by factors, such as increasing R&D and extensive usage of miRNA in cancer detection

• Based on applications, cancer diagnostics dominated the market with market in 2022 due to the rising prevalence of cancer among the population

• Asia Pacific is expected to register the fastest CAGR over the forecast period due to the rising prevalence of target diseases, improving healthcare facilities, and growing demand for IVD testing for disease detection

Fluorescent in Situ Hybridization Probe Market Segmentation

Grand View Research has segmented the global fluorescent in situ hybridization probe market on the basis of the technology, type, application, end-use, and region:

Fluorescent in Situ Hybridization (FISH)  Probe Technology Outlook (Revenue, USD Million, 2018 - 2030)

• FLOW FISH

• Q FISH

• Other FISH

Fluorescent in Situ Hybridization (FISH)  Probe Type Outlook (Revenue, USD Million, 2018 - 2030)

• DNA

• RNA

  • mRNA

  • miRNA

  • Other

Fluorescent in Situ Hybridization (FISH)  Probe Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer Research

  • Lung

  • Breast

  • Bladder

  • Hematological

  • Gastric

  • Prostrate

  • Cervical

  • Other

• Genetic Diseases

• Other

Fluorescent in Situ Hybridization (FISH)  Probe End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Research

• Clinical

• Companion Diagnostics

Fluorescent in Situ Hybridization (FISH)  Probe Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Fluorescent in Situ Hybridization Probe Market

• Thermo Fisher Scientific Inc.

• Perkinelmer Inc.

• BioDot

• Horizon Diagnostics

• Agilent Technologies, Inc.

• Abnova Corporation

• LGC Biosearch Technologies

• Genemed Biotechnologies, Inc.

• Oxford Gene Technology IP Limited

• Biocare Medical, LLC.

• QIAGEN (Exiqon A/S)

• GSP Research Institute, Inc.